Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 7Phase 1 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 250Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 118Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 47Carcinoma, Renal Cell 45Leukemia, Lymphocytic, Chronic, B-Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Nasopharyngeal Carcinoma 34Lymphoma, Follicular 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Endometrial Neoplasms 29

Interventions

Tegafur 1S 1 (combination) 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Klatskin Tumor × 1 year × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡